Notice of Allowability	Application No. Applicant(s)			
	09/871,491	RAULET ET AL.	RAULET ET AL.	
	Examiner	Art Unit		
	Alana M. Harris, Ph.D.	1642		
The MAILING DATE of this communication and All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOLNOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.	IS (OR REMAINS) CLOSED in 85) or other appropriate communities. This application is su	this application. If not included nication will be mailed in due co	urse. THIS	
1. This communication is responsive to <u>June 7, 2004</u> .				
2. ☑ The allowed claim(s) is/are <u>39,45,51 and 53</u> .				
3. The drawings filed on are accepted by the Exam	iner.			
 4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the: Certified copies of the priority documents here. Certified copies of the priority documents here. Copies of the certified copies of the priority International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DAT	ave been received. ave been received in Applicatior documents have been received	ı No in this national stage application		
noted below. Failure to timely comply will result in ABANDO THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be su	bmitted. Note the attached EXA		ΓICE OF	
INFORMAL PATENT APPLICATION (PTO-152) which	gives reason(s) why the oath or	declaration is deficient.		
 CORRECTED DRAWINGS (as "replacement sheets") r (a) including changes required by the Notice of Draftsp 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examin Paper No./Mail Date Identifying indicia such as the application number (see 37 CF each sheet. Replacement sheet(s) should be labeled as such 	person's Patent Drawing Review per's Amendment / Comment or it R 1.84(c)) should be written on the	n the Office action of e drawings in the front (not the ba	ack) of	
 DEPOSIT OF and/or INFORMATION about the de attached Examiner's comment regarding REQUIREMENT 			e the	
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-94) 3. Information Disclosure Statements (PTO-1449 or PTO/S Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Depos of Biological Material	8) 6. 🛛 Interview Su Paper No./M B/08), 7. 🖾 Examiner's A	Mail Date <u>08/16/04</u> . Amendment/Comment Statement of Reasons for Allowa	ance .D.	

Art Unit: 1642

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Richard Aron Osman, J.D., Ph.D. on 16 August 2004.

The application has been amended as follows:

- 2. Claim 39 has been replaced with the following claim:
 - -- 3Ø. (Currently amended) A method for inhibiting prostate tumor growth in a mammalian host determined to have a metastatic prostate tumor and comprising prostate tumor cells expressing native NKG2D, the method comprising steps:

administering to the mammalian host a host-compatible cell transduced to express on the surface of the cell a plurality of NKG2D-binding moieties of natural NKG2D ligands selected from the group consisting of MICA, MICB and ULBP, wherein the administering step is effective to inhibit growth of the tumor; and detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.—-

Claim 51 has been replaced with the following claim:

--51. (Currently amended) A method for inhibiting primary mammary tumor growth in a mammalian host determined to have a primary mammary tumor and comprising mammary tumor cells expressing native NKG2D, the method comprising steps:

administering to the mammalian host a host-compatible cell transduced to express on the surface of the cell a plurality of NKG2D-binding moieties of natural NKG2D ligands selected from the group consisting of MICA, MICB and ULBP, wherein the administering step is effective to inhibit growth of the tumor; and detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.--

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The examiner works a flexible schedule, however she can normally be reached between the hours of 6:30 am to 5:30 pm, with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ALANA M. HARRIS, PH.D. PRIMARY EXAMINER

Alana M. Harris, Ph.D. 16 August 2004